Psyence Pushes Back Stock Split Consolidation; Shares Decline

PessimisticOracle · 2026-03-11T00:18:18+00:00

Psyence Biomedical Ltd. has delayed its 1-for-6.25 stock split to February 2, 2026, from January 20, causing a 5.05% drop in shares. The decision follows an internal review and aims for better trading dynamics by reducing outstanding shares.

PessimisticOracle

2026-03-11 00:18:18

Abstract generation in progress

Psyence Biomedical Ltd. (PBM) has postponed its 1-for-6.25 stock split consolidation to February 2, 2026, moving the effective date back from the initially planned January 20, 2026. The announcement triggered a market reaction, with PBM shares falling 5.05% to $0.73 in after-hours trading. The company’s decision followed internal strategic review, prompting the delay of what had been an already-approved corporate action.

The Consolidation Plan and Timeline Shift

In December 2025, Psyence’s board approved the 1-for-6.25 reverse stock split consolidation, designed to reduce the number of outstanding shares and adjust the stock price structure. Originally set to begin trading on a post-consolidated basis at the January 20, 2026 market open, the company opted to extend this timeline. The new effective date is now February 2, 2026, when shareholders will begin trading consolidated shares under the same PBM ticker on the Nasdaq Capital Market.

Stock Performance and Share Restructuring Impact

As of January 21, 2026, Psyence had 6.39 million common shares outstanding. Following the consolidation, this number will be reduced to 1.02 million shares—a significant restructuring that reflects the mechanics of the 1-for-6.25 stock split consolidation. Each investor holding shares will see their position consolidated, with every 6.25 existing shares automatically combining into one new share. The market’s immediate response to the postponement news demonstrated investor sensitivity to timing changes in corporate restructuring actions, with Wednesday’s close showing a 22.01% gain prior to this announcement.

Trading Details and Updated Identifiers

Upon consolidation completion, Psyence’s shares will receive a new CUSIP identification number (74449F407) while maintaining its Nasdaq Capital Market listing under the PBM symbol. The stock split consolidation represents a standard capital restructuring approach for companies seeking to adjust their share structure and potentially improve trading dynamics. The postponement allows additional time for the company to finalize all procedural requirements before the new February consolidation date takes effect.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes